Dr. Reddy Stock To Go Ex-dividend Tomorrow (RDY)

NEW YORK ( TheStreet) -- The ex-dividend date for Dr. Reddy Laboratories (NYSE: RDY) is tomorrow, June 27, 2012. Owners of shares as of market close today will be eligible for a dividend of 21 cents per share. At a price of $28 as of 10:05 a.m. ET, the dividend yield is 0.8%.

The average volume for Dr. Reddy has been 255,700 shares per day over the past 30 days. Dr. Reddy has a market cap of $4.7 billion and is part of the health care sector and drugs industry. Shares are down 5.8% year to date as of the close of trading on Monday.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company worldwide. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The company has a P/E ratio of 19, above the average drugs industry P/E ratio of 16.8 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Dr. Reddy as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. You can view the full Dr. Reddy Ratings Report.

See our dividend calendar or top-yielding stocks list.
null

If you liked this article you might like

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume